Clinical trial
ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer
NCT00387608 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00387608 |
|---|---|
| Title | ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer |
| Official title | A Phase 0 Pharmacokinetic, Pharmacodynamic Study of ABT-888, an Inhibitor of Poly (ADP-ribose) Polymerase (PARP), in Refractory Solid Tumors and Lymphoid Malignancies |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other, Procedure |
| Interventions | veliparib, pharmacological study, biopsy |
| Enrollment | 23 |
| Start date | Jun 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Oct 13, 2006 |
| Last update posted | Mar 15, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: